bat6026
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05105971)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFSF4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06094179 | Phase 1/Phase 2 (Phase 2) | Nov 9, 2023 | Biothera |
| NCT05109650 | Phase 1 | Dec 15, 2021 | Biothera, Scientia Clinical Research Limited Sydney |
| NCT05105971 | Phase 1 | Nov 30, 2021 | Biothera, Sun Yat-Sen University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biothera | For profit | 3 | 3 | 2 | 2021 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1